Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system.

@article{Oliver2009NeurodevelopmentalOF,
  title={Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system.},
  author={Sara E. Oliver and Gretchen A. Cloud and Pablo J. S{\'a}nchez and Gail J Demmler and Wayne N Dankner and Mark Shelton and Richard F. Jacobs and Wendy L Vaudry and Robert F Pass and Seng-jaw Soong and Richard J. Whitley and David W. Kimberlin},
  journal={Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
  year={2009},
  volume={46 Suppl 4},
  pages={S22-6}
}
BACKGROUND Ganciclovir protects against hearing deterioration in infants with symptomatic congenital cytomegalovirus (CMV) disease involving the central nervous system (CNS). OBJECTIVES To assess the neurodevelopmental impact of ganciclovir therapy in this population. STUDY DESIGN 100 neonates were enrolled into a controlled Phase III study of symptomatic congenital CMV involving the CNS, and were randomized to either 6 weeks of intravenous ganciclovir or no treatment. Denver developmental… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

Cytomegalovirus infection in pregnancy

Archives of Gynecology and Obstetrics • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…